Advertisement

Loading...

Curaleaf Holdings, Inc.

CURA.CNCNQ
Healthcare
Drug Manufacturers - Specialty & Generic
$5.22
$0.44(9.21%)
Canadian Market opens in 16h 33m

Curaleaf Holdings, Inc. Fundamental Analysis

Curaleaf Holdings, Inc. (CURA.CN) shows weak financial fundamentals with a PE ratio of -11.50, profit margin of -19.17%, and ROE of -28.10%. The company generates $1.8B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

PEG Ratio-0.11

Areas of Concern

ROE-28.10%
Operating Margin0.86%
Cash Position3.53%
We analyze CURA.CN's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -33.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-33.9/100

We analyze CURA.CN's fundamental strength across five key dimensions:

Efficiency Score

Weak

CURA.CN struggles to generate sufficient returns from assets.

ROA > 10%
-8.64%

Valuation Score

Excellent

CURA.CN trades at attractive valuation levels.

PE < 25
-11.50
PEG Ratio < 2
-0.11

Growth Score

Weak

CURA.CN faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

CURA.CN shows balanced financial health with some risks.

Debt/Equity < 1
1.21
Current Ratio > 1
1.47

Profitability Score

Weak

CURA.CN struggles to sustain strong margins.

ROE > 15%
-2810.20%
Net Margin ≥ 15%
-19.17%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is CURA.CN Expensive or Cheap?

P/E Ratio

CURA.CN trades at -11.50 times earnings. This suggests potential undervaluation.

-11.50

PEG Ratio

When adjusting for growth, CURA.CN's PEG of -0.11 indicates potential undervaluation.

-0.11

Price to Book

The market values Curaleaf Holdings, Inc. at 3.32 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

3.32

EV/EBITDA

Enterprise value stands at 9.04 times EBITDA. This is generally considered low.

9.04

How Well Does CURA.CN Make Money?

Net Profit Margin

For every $100 in sales, Curaleaf Holdings, Inc. keeps $-19.17 as profit after all expenses.

-19.17%

Operating Margin

Core operations generate 0.86 in profit for every $100 in revenue, before interest and taxes.

0.86%

ROE

Management delivers $-28.10 in profit for every $100 of shareholder equity.

-28.10%

ROA

Curaleaf Holdings, Inc. generates $-8.64 in profit for every $100 in assets, demonstrating efficient asset deployment.

-8.64%

Following the Money - Real Cash Generation

Operating Cash Flow

Curaleaf Holdings, Inc. produces operating cash flow of $195.31M, showing steady but balanced cash generation.

$195.31M

Free Cash Flow

Curaleaf Holdings, Inc. produces free cash flow of $71.19M, offering steady but limited capital for shareholder returns and expansion.

$71.19M

FCF Per Share

Each share generates $0.09 in free cash annually.

$0.09

FCF Yield

CURA.CN converts 1.70% of its market value into free cash.

1.70%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-11.50

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.11

vs 25 benchmark

P/B Ratio

Price to book value ratio

3.32

vs 25 benchmark

P/S Ratio

Price to sales ratio

2.27

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

1.21

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.47

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.28

vs 25 benchmark

ROA

Return on assets percentage

-0.09

vs 25 benchmark

ROCE

Return on capital employed

0.004

vs 25 benchmark

How CURA.CN Stacks Against Its Sector Peers

MetricCURA.CN ValueSector AveragePerformance
P/E Ratio-11.5027.91 Better (Cheaper)
ROE-28.10%687.00% Weak
Net Margin-19.17%-45285.00% (disorted) Weak
Debt/Equity1.210.33 Weak (High Leverage)
Current Ratio1.472795.76 Neutral
ROA-8.64%-13557.00% (disorted) Weak

CURA.CN outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Curaleaf Holdings, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ